Regenxbio RGNX Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $170.44M+105% | $83.33M-7.7% | $90.24M-19.9% | $112.72M-76.0% | ||
| $228.3M+9.5% | $208.52M-10.2% | $232.27M-4.2% | $242.45M+33.6% | ||
| $82.86M+8.1% | $76.62M-13.4% | $88.49M+3.8% | $85.28M+7.5% | ||
| $331.64M+4.7% | $316.67M-11.6% | $358.37M-4.6% | $375.6M+21.0% | ||
| -$161.2M+30.9% | -$233.35M+13.0% | -$268.13M-2.0% | -$262.88M-264% | ||
| -94.6%+185pp | -280%+17.1pp | -297.1%-63.9pp | -233.2%-267pp | ||
| $45.01M+256% | $12.66M+84.5% | $6.86M-70.5% | $23.25M-11.5% | ||
| -$32.68M-623% | $6.24M+39.3% | $4.48M+126% | -$17.53M+6.4% | ||
| -$193.88M+14.6% | -$227.1M+13.8% | -$263.49M+6.0% | -$280.32M-319% | ||
| -113.8%+159pp | -272.5%+19.4pp | -292%-43.3pp | -248.7%-276pp | ||
| -$3.76+18.3% | -$4.60+23.6% | -$6.02+7.5% | -$6.51-324% | ||
| -$145.58M+33.0% | -$217.13M+13.4% | -$250.81M-0.3% | -$249.97M-247% | ||
| -85.4%+175pp | -260.6%+17.4pp | -277.9%-56.2pp | -221.8%-258pp | ||
| -$161.2M+30.9% | -$233.35M+13.0% | -$268.13M-2.0% | -$262.88M-264% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Regenxbio's revenue?
- Regenxbio (RGNX) generated $87.8M in revenue over the trailing twelve months, down 44.0% year over year.
- Is Regenxbio profitable?
- Regenxbio is not currently profitable: it reported a net loss of $290.0M over the trailing twelve months, a -330.2% net margin.
- What are Regenxbio's profit margins?
- Gross margin is 59.7% and operating margin is -292.3%, with a -330.2% net margin.
- What is Regenxbio's earnings per share?
- Regenxbio's diluted EPS over the trailing twelve months is $-5.60.
- Where does Regenxbio's income statement data come from?
- Every line is extracted from Regenxbio's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
